Trial Profile
A phase 2 study of larazotide acetate for the treatment of Nonalcoholic steatohepatitis (NASH)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2018
Price :
$35
*
At a glance
- Drugs Larazotide (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Innovate Biopharmaceuticals
- 06 Nov 2018 New trial record
- 29 Oct 2018 According to an Innovate Biopharmaceuticals media release, the company expects to initiate this study in 2019.